News
Competition heats up in BCMA CAR-T as J&J, BMS update myelom...
Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, accord
